Dimensional Fund Advisors LP Acquires 295,594 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)

Dimensional Fund Advisors LP boosted its position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 19.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,855,036 shares of the company's stock after purchasing an additional 295,594 shares during the quarter. Dimensional Fund Advisors LP owned about 1.29% of Denali Therapeutics worth $37,805,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of DNLI. Vanguard Group Inc. raised its position in shares of Denali Therapeutics by 7.6% in the fourth quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company's stock worth $244,993,000 after buying an additional 843,996 shares in the last quarter. FMR LLC raised its holdings in shares of Denali Therapeutics by 2.4% in the 4th quarter. FMR LLC now owns 8,019,746 shares of the company's stock valued at $163,442,000 after acquiring an additional 188,368 shares in the last quarter. Alliancebernstein L.P. boosted its position in shares of Denali Therapeutics by 8.8% during the 4th quarter. Alliancebernstein L.P. now owns 3,315,642 shares of the company's stock valued at $67,573,000 after acquiring an additional 268,378 shares during the last quarter. Principal Financial Group Inc. grew its holdings in shares of Denali Therapeutics by 13.8% during the third quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company's stock worth $36,076,000 after purchasing an additional 149,939 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of Denali Therapeutics during the fourth quarter worth about $21,717,000. 92.92% of the stock is owned by institutional investors.

Denali Therapeutics Trading Up 2.1 %

Denali Therapeutics stock traded up $0.29 during trading hours on Wednesday, hitting $14.26. 1,841,465 shares of the stock traded hands, compared to its average volume of 1,094,757. Denali Therapeutics Inc. has a one year low of $10.57 and a one year high of $33.33. The company has a market cap of $2.07 billion, a PE ratio of -5.17 and a beta of 1.49. The firm's 50-day moving average price is $14.32 and its two-hundred day moving average price is $20.24.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.78) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.07). During the same quarter in the prior year, the company earned ($0.68) earnings per share. On average, sell-side analysts expect that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have commented on DNLI. The Goldman Sachs Group cut their price target on shares of Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating for the company in a research note on Tuesday, January 28th. Bank of America reduced their target price on Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating on the stock in a research note on Monday, March 10th. HC Wainwright dropped their price target on Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday. Morgan Stanley started coverage on Denali Therapeutics in a report on Friday, March 7th. They set an "overweight" rating and a $33.00 price objective on the stock. Finally, B. Riley reaffirmed a "buy" rating and issued a $35.00 target price (down previously from $38.00) on shares of Denali Therapeutics in a research note on Wednesday, March 5th. One investment analyst has rated the stock with a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Buy" and an average price target of $33.93.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.